Skip to content
Search

Latest Stories

NHS England rolls out more sensitive cervical screening test

A new and more sensitive cervical screening test has the “potential” to eliminate cervical cancer, NHS England said.

The test looks for traces of high-risk Human Papillomavirus (HPV), and any tests that are HPV positive are then checked for abnormal changes of the cervix.


It is already launched across the country since December and is part of the NHS Long Term Plan goal to catch tens of thousands of more cancer cases earlier.

Jo Churchill, Public Health Minister, said: “Thousands fewer women will be diagnosed with cervical cancer as a result of improved screening services and the HPV vaccine and it’s incredible to think that cervical cancer could be eradicated for good.”

A Public Health England report, published today, shows that the number of HPV infection decreased to very low levels since the introduction of HPV vaccination in 2018.

The combination of HPV vaccine’s effectiveness and the new test has the “potential to eliminate cervical cancer," NHS said.

Professor Anne Mackie, Director of Screening at Public Health England, added: “With HPV vaccinations for all year 8 pupils and HPV testing available nationally, cervical cancer promises to become very rare indeed. This is a truly momentous achievement, but to ensure we consign this disease to the past we must keep vaccination rates high and continue to provide safe and acceptable screening for all women.”

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less